GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer

GLYCO-IMMUNE CHECKPOINT INHIBITORS

The Need

Despite the early success of first-generation immuno-oncology drugs, most cancer patients still do not achieve clinical responses.

Learn more

The Scientific Opportunity

Cell surface glycosylation is now known to play a central role in immuno-oncology: Tumor cells evolve over time, cloaking themselves in certain glycan patterns that down-regulate a wide spectrum of innate and adaptive immune cell types which are critical to fighting cancer.

Learn more

The Approach

Palleon Pharmaceuticals has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glyco-Immune Checkpoint Inhibitors to treat cancer patients.

Learn more

Twitter

@Palleon_Pharma
We're hiring! Do you have an interest in developing biomarker assays for a fast-paced #ImmunoOncology startup? We'r… http://WkKosiWSCB

@Palleon_Pharma
Check out this excellent summary of Palleon scientific board member Heinz Laubli's recent article in… http://nBgtcuCHag

Visit us on Twitter